Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling
American Journal of Cancer Research · 2026 · 16 (6) · 2389-2406
DOI: 10.62347/curf9339 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2026. Verfasst von Thomas G Mhone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien, Taiwan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien, Taiwan.
- Center for Molecular Medicine in Traditional Chinese Medicine, E-Da Hospital, E-Da Healthcare Group Kaohsiung, Taiwan.
- Department of Biological Science and Technology, College of Life Sciences, China Medical University Taichung, Taiwan.
- School of Pharmacy, China Medical University Taichung, Taiwan.
- Laboratory of Exercise Biochemistry, The Education University of Hong Kong New Territories, Hong Kong.
- Soochow University, School of Physical Education and Sports Science Suzhou, Jiangsu, China.
Zitieren
APA
Mhone, T. G., Kuo, W. W., Chi, C. Y., Kuo, C. H., Ho, T. J., Wu, Y. L., Lin, Y. M., Chen, M. C., Huang, C. Y., & Lin, S. Z. (2026). Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling. American Journal of Cancer Research, 16(6), 2389-2406. https://doi.org/10.62347/curf9339
Vancouver
Mhone TG, Kuo WW, Chi CY, Kuo CH, Ho TJ, Wu YL, et al. Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling. American Journal of Cancer Research. 2026;16(6):2389-2406. doi:10.62347/curf9339
BibTeX
@article{Mhone2026,
author = {Mhone, Thomas G and Kuo, Wei-Wen and Chi, Chih-Ying and Kuo, Chia-Hua and Ho, Tsung-Jung and Wu, Yu-Ling and Lin, Yueh-Min and Chen, Ming-Cheng and Huang, Chih-Yang and Lin, Shinn-Zong},
title = {Kang Ru Plus reverses osimertinib resistance in lung adenocarcinoma via suppression of EGFR/PI3K/AKT signaling},
journal = {American Journal of Cancer Research},
year = {2026},
volume = {16},
number = {6},
pages = {2389--2406},
doi = {10.62347/curf9339}
}
EUVIMED